Alnylam Pharmaceuticals (ALNY) PT Lowered to $160 at BMO Capital
February 8, 2018 12:41 PM
BMO Capital lowered its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $160.00 (from $165.00) while maintaining an Outperform rating.Analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
